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DObjective: Stentless xenograft bioprostheses may be the future valve of choice for aortic valve replacement. The
study aim was to investigate the long-term clinical outcome after aortic valve replacement with the Medtronic
Freestyle bioprosthesis (Medtronic Inc, Minneapolis, Minn).
Methods: Between April 1997 and November 2004, a total of 500 patients (mean age, 74.5  9.6 years; 52%
were male) underwent aortic valve replacement with a Freestyle bioprosthesis, without population selection.
The surgical procedure used a modified subcoronary technique in 479 patients and a complete root replacement
in 21 patients, conducted with mini-extracorporeal circulation. Concomitant procedures included coronary
artery bypass grafting in 122 patients (24%) and mitral valve repair/replacement in 11 patients.
Results: The mean cardiopulmonary bypass time was 98 26 minutes, and total aortic crossclamp time was 77
 19 minutes. Operative mortality was 5.2%. The median follow-up time was 104.8  5.7 months. During this
period, there were 224 deaths (n ¼ 122 cardiovascular and n ¼ 102 noncardiovascular deaths). The actuarial
survivals from cardiovascular and valve-related mortality were 67%  3% and 70%  4%, respectively, at
10 years. Freedom from structural valve deterioration at 10 years was 94%  2%. The linearized structural
valve deterioration incidence was 0.6% per patient/year. Multivariate Cox regression analysis revealed that
older age, impaired renal function, and coronary artery disease were independent predictors of cardiovascular
death. In the subgroup of patients aged less than 65 years at implantation (n ¼ 45), the actuarial cardiovascular
survival was 83%  8% and freedom from structural valve deterioration was 89%  6% at 10 years.
Conclusions: The use of the Freestyle bioprosthesis for aortic valve replacement resulted in good long-term
cardiovascular survival and freedom from structural valve deterioration in this cohort regardless of age at
implantation. (J Thorac Cardiovasc Surg 2014;148:1903-11)See related commentary on pages 1911-2.The use of bioprostheses for aortic valve replacement (AVR)
is recommended by international guidelines in patients aged
more than 65 years, because of the decreased risk of device
structural deterioration and the absence of required anticoa-
gulation in this population with high risk for bleeding.1
Bioprostheses can be broadly divided into 2 categories
according to the presence or absence of a metallic stent
supporting the biological tissue leaflet. The choice of a
stented or stentless device for AVR remains debated,
because they are purported to confer advantages over their
counterparts.1e Cardiology Departmenta and Cardiac Surgery Department,b Centre Chirur-
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The Journal of Thoracic and CarThe Freestyle stentless (Medtronic Inc, Minneapolis,
Minn) aortic bioprosthesis is a xenograft composed of a
thin synthetic sewing cuff attached to a glutaraldehyde-
preserved porcine aortic root using an alpha-amino oleic
acid leaflet anti-calcification treatment. The absence of
stent has been reported to provide better hemodynamic
properties compared with stented biological valves, with
less turbulent flow and larger efficient effective orifice
area.2 These characteristics could lead to lower transvalvu-
lar gradient and better valve duration.2 Thus, the use of
stentless bioprostheses (SLBs) might improve survival,
reduce the structural deterioration risk, and minimize dele-
terious long-term impact on left ventricle function. Recent
results from randomized trials and meta-analysis suggest
a superiority of stentless over stented biological standard
bioprostheses,3,4 especially in patients with left ventricle
dysfunction and a small aortic annulus.2
Despite the introduction of SLBs in the early 1990s, long-
term outcome data are still required to assess their durability
and safety.1 Our group previously reported excellent short-
and mid-term survivals in patients of a wide age range.5 The
purpose of the present study was to describe the clinical
outcome in a large cohort of all-comer patients who
received a Freestyle bioprosthesis implantation and were
prospectively followed up for as long as 12 years.diovascular Surgery c Volume 148, Number 5 1903
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CSB ¼ conventional stented bioprosthesis
LVEF ¼ left ventricular ejection fraction
SLB ¼ stentless bioprosthesis
SVD ¼ structural valve deterioration
TAVI ¼ transaortic valve implantation
VKA ¼ vitamin K antagonist
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Patient Population
This prospective observational cohort study included patients who
benefited from Freestyle bioprostheses implantation by 2 surgeons
(O.M.B. and P.H.D.) working together in 2 institutions between April
1997 and November 2004.5 To provide realistic clinical results, the Free-
style bioprosthesis was used immediately after a choice of biological pros-
thetic valves had been made, with no selection on age, left ventricular
function, or operative risk. Therewas no specific inclusion or exclusion cri-
terion for Freestyle implantation in this all-comers cohort. Our local ethics
committee approved the study, and informed signed consent was obtained.
Operative Technique
Cardiopulmonary bypass was conducted with a mini-extracorporeal cir-
culation circuit (Jostra MECC System; Jostra AG, Hirrlingen, France), sys-
temic normothermia, and warm antegrade discontinued blood cardioplegia.
The Freestyle bioprosthesis was implanted using the modified subcoronary
technique6 or the complete aortic root replacement with coronary artery re-
implantation.7 Our first option was the subcoronary technique (‘‘cylinder in
a cylinder’’) to optimize the procedure of AVR by shortening the cardiopul-
monary bypass and aortic crossclamp times. The full root replacement
technique was performed in case of aortic root dilation.
In all techniques, a transverse aortotomy was used. In the subcoronary
technique, the inflow of the porcine root was secured with simple interrup-
ted sutures. The porcine valve was trimmed by excision of the remnants of
the aortic tissue above the orifices for the coronary sinuses, leaving the non-
coronary sinus wall intact. In case of a small aortic annulus and low right
coronary ostium, the Freestyle device was rotated to avoid the potential
obstruction created by the folded fabric cloth covering the muscle bar of
the prosthesis.6 In the total root replacement, the aorta was transected above
the sinotubular ridge. Both coronary ostia were mobilized with buttons of
aortic wall. The remaining tissue of the sinus of Valsalva was excised. A
quadrangular portion of the porcine aortic sinus was excised to remove
the porcine coronary artery for both the left and right coronary arteries.
The porcine valve was rotated to allow optimal right coronary artery im-
plantation in the Freestyle noncoronary wall. The coronary buttons were
sewn to the corresponding sinus of Valsalva with a continuous suture, and
the outflow portion of the graft was sutured to the crest of the native aorta.
During the same period, the Freestyle bioprosthesis could not be im-
planted in a subcoronary fashion in 30 patients because of technical contra-
indications. These included heavy calcification of the native aortic wall
itself and calcifications localized beneath the coronary ostia, both of which
compromised the upper suture of the stentless valve. Problems were also
encountered in redo aortic operations when the aortotomy could not always
be performed at the appropriate location.Clinical and Echocardiography Data
Preoperative clinical and surgical data were recorded prospectively for
each patient. Preoperative and postoperative echocardiographic data were1904 The Journal of Thoracic and Cardiovascular Surobtained according to the international guidelines and included left
ventricle ejection fraction, mean transvalvular gradient measurement,
and effective orifice area calculation.8 The following variables were
considered as potential outcome determinants: age, gender, body mass in-
dex, body surface area, diabetes, preoperative renal function (estimated by
the Modification of Diet in Renal Disease calculation of the creatinine
clearance), concomitant procedure, operative technique, re-replacement
of the aortic valve, physiologic subgroup as aortic stenosis, aortic insuffi-
ciency or combined aortic valve disease, history of endocarditis, previous
cardiac surgery, valve size, baseline pre-intervention transaortic gradient,
left ventricular ejection fraction (LVEF), and preoperative pulmonary
hypertension.
Anticoagulation Regimen
Our policy regarding anticoagulation followed the European Society of
Cardiology guidelines.9 Oral anticoagulation with vitamin K antagonists
(VKAs) was provided to patients with chronic and recurrent atrial fibrilla-
tion. Although the decision to give or not give VKAs to elderly patients was
left to the discretion of the cardiologist, the general consensus in France at
this time was to switch from VKA to aspirin in subjects aged more than 85
years. Other subjects with previous coronary artery disease or at high
cardiovascular risk received aspirin therapy (75 mg/d) after surgery.
Follow-up Data Analysis
Outcomes were analyzed according to the guidelines of the American
Association for Thoracic Surgery for reporting morbidity and mortality
after cardiac valvular operations.10 Follow-up information was obtained
by a single investigator between April 1997 and July 2010, using a stan-
dardized interview or telephone questionnaire. Data regarding all-cause,
cardiac, and valve-related mortalities, structural valvular deterioration,
operated valvular endocarditis, bleeding events, and thromboembolic
events were collected and integrated into our database.
Statistical Analysis
Statistical analysis was performed with SPSS 21.0 (SPSS Inc, Chicago,
Ill) and SAS 9.33 (SAS Institute Inc, Cary, NC). Data are expressed as
mean and standard deviation.
Patient survivals from all-cause, cardiovascular, and valve-related mor-
talities, and structural valve deterioration (SVD) were analyzed, and
Kaplan–Meier actuarial survival curves were constructed. In addition, we
performed cumulative actual incidence analysis of SVD to provide a
mortality-adjusted event-free percentage.11 Differences between survival
curves were evaluated using the log-rank test.
We used a multivariate Coxmodel with stepwise regression to assess the
relation of covariates with the incidence of the different clinical end points
during follow-up. Univariate Cox proportional hazards regression analyses
were first performed among established predictors of long-term cardiovas-
cular mortality. All covariates with a P value less than .1 were then included
in the multivariate regression model to identify independent predictors of
the primary end point. The validity of the proportionality assumption
was verified for all covariates by the likelihood ratio test. A 2-sided alpha
level of 0.05 was considered the threshold for statistical significance.RESULTS
Baseline Characteristics
Between April 1997 and November 2004, a total of 850
patients underwent AVR by the 2 selected surgeons. Among
them, 500 patients (age range, 26-91 years) underwent AVR
with implantation of a Freestyle bioprosthesis, 30 patients
underwent AVR with implantation of another bioprosthesis
because of Freestyle implantation impossibility, and 320gery c November 2014
TABLE 1. Baseline clinical and echography characteristics of the
study population
Parameter N ¼ 500
Age (y) 74.5  9.6
Male gender, n (%) 259 (52)
Significant coronary artery disease, n (%) 178 (35)
Diabetes mellitus, n (%) 110 (22)
Peripheral artery disease, n (%) 60 (12)
Creatinine clearance 60 mL/min/m2, n (%) 135 (27)
Body mass index (kg/m2) 26.7  13.6
Body surface area (m2) 1.78  0.23
Previous cardiac surgery, n (%) 10 (2)
Previous AVR, n (%) 4 (1)
Indications for AVR, n (%)
Aortic stenosis with underlying tricuspid valve, n (%) 426 (85)
Aortic stenosis with underlying bicuspid valve, n (%) 13 (3)
Isolated aortic regurgitation, n (%) 37 (7)
Combined aortic valve disease, n (%) 14 (3)
Active endocarditis without aortic regurgitation, n (%) 3 (0.5)
Active endocarditis with aortic regurgitation, n (%) 7 (1.5)
Aortic dissection, n (%) 0
NYHA class, n (%)
I/II 295 (59)
III/IV 205 (41)
Left ventricle ejection fraction (%) 58.6  0.8
Preoperative pulmonary hypertension, n (%) 100 (20)
Mean preoperative transaortic gradient (mm Hg) 52.0  15.6
AVR, Aortic valve replacement; NYHA, New York Heart Association.
TABLE 2. Operative and postoperative characteristics
Parameter N ¼ 500
Cardiopulmonary bypass time (min) 98.5  26.0
Total aortic crossclamp time (min) 77.3  19.3
Prosthesis diameter (mm) 22.2  2.2
Valve size, n (%)
19 mm 82 (16)
21 mm 160 (32)
23 mm 159 (32)
25 mm 78 (15.5)
27 mm 19 (4)
29 mm 2 (0.5)
Freestyle implantation technique
Modified subcoronary technique, n (%) 479 (96)
Complete root replacement, n (%) 21 (4)
Associated procedure, n (%) 157 (31)
Coronary artery bypass graft, n (%) 122 (24)
Mitral valve replacement, n (%) 3 (1)
Mitral valvuloplasty, n (%) 8 (2)
Ascending aortic tube-graft, n (%) 9 (2)
Other, n (%) 15 (3)
Anticoagulation regimen at discharge
None, n (%) 215 (43)
VKA, n (%) 102 (20)
Aspirin, n (%) 285 (57)
VKA, Vitamin K antagonist.
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prosthesis. Patients implanted after this period with a Free-
style device (n ¼ 600) were not included in the study
because it was focused on long-term outcome. The baseline
characteristics of the population are shown in Table 1.Operative Data
The modified subcoronary implantation technique was
used in 479 patients (96%). The mean cardiopulmonary
bypass time was 98  26 minutes (88  15 minutes for
AVR alone), and the mean aortic crossclamp time was 77
 19 minutes (70  13 minutes for AVR alone) (Table 2).
Both mean cardiopulmonary bypass time and aortic cross-
clamp times were significantly longer in the patients with
complete root replacement versus modified subcoronary
implantation (128 34minutes vs 97 25minutes, respec-
tively, and 99  25 minutes vs 76  19 minutes, respec-
tively, P< .001 for both). A concomitant procedure was
performed in 31% of the cases. The remaining patients
with coronary disease (10%) did not undergo coronary ar-
tery bypass grafting because the target lesions were distal
or secondary. The mean Freestyle bioprosthesis diameter
was 22.2  2.2 mm. A total of 242 (48%) small-diameter
bioprostheses (19 or 21 mm) were used, mostly in the older
female group.The Journal of Thoracic and CarOperative Mortality and Early Outcome
Twenty-six (5.2%) perioperative deaths occurred
during the initial hospitalization or within 30 days after
surgery. No death occurred in the younger age group
(<65 years). Five of 120 patients aged more than 80 years
died (4%).
Long-Term Outcome
Follow-up was achieved in 488 patients (median follow-
up, 104.8 5.7 months; range, 1-155 months; 2971 patient-
years). During this period, there was a total of 224 all-cause
deaths, including 122 cardiovascular and 109 valve-related
deaths (n¼ 11 deaths caused by structural and nonstructural
dysfunction, n ¼ 8 fatal embolic events, n ¼ 14 fatal hem-
orrhagic events, n ¼ 4 fatal endocarditis, n ¼ 19 sudden
death, and n ¼ 53 unexplained death). Figure 1, A shows
the Kaplan–Meier curves for long-term survival among
the whole cohort. The actuarial survivals for all-cause, car-
diovascular, and valve-related mortality were 44%  3%,
67%  3%, and 70%  4% at 10 years, respectively,
and 31%  5%, 50%  7%, and 58%  7% at 12 years,
respectively.
Evidence of SVD was identified in 18 patients and led to
reintervention in 10 subjects. The actuarial freedom from
SVD was 94%  2% (Figure 1, B), and the actual cumula-
tive incidence of SVD (Figure 1, C) was 3.7% at 10 years.
The poorer actuarial rates reflected the burden of competingdiovascular Surgery c Volume 148, Number 5 1905
FIGURE 1. Kaplan–Meier actuarial survival curves for all-cause, cardiovascular, valve-related mortality (A), and SVD (B) in the global cohort (n¼ 488).
Cumulative incidence of SVD (C). SVD, Structural valve deterioration.
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the occurrence of SVD.
The pathologic assessment of the explanted bioprosthesis
indicated that the mechanism responsible for valve failure
was the association of leaflet calcification and tear in1906 The Journal of Thoracic and Cardiovascular Sur60% of patients, leaflet tear in 20% of patients, and pre-
dominant calcification of leaflet and commissures in the re-
maining 20% of patients. The linearized annual incidence
of SVD was 0.6% per patient/year. In addition, reoperation
was required in 10 cases that were not related to SVD.gery c November 2014
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(linearized annual incidence: 0.5% per patient/year; actu-
arial freedom from endocarditis: 96%  1%, at 10 years),
leading to death in 4 cases. There was no case of valve
thrombosis observed during follow-up. A total of 25 pa-
tients presented peripheral thromboembolism (mean age,
77  14.7 years; 53% male gender/linearized annual inci-
dence: 0.8% per patient/year; actuarial freedom from
peripheral embolic event 90% 3% at 10 years), including
stroke in 17, transient ischemic attack in 5, mesenteric
ischemia in 1, and acute central retinal artery occlusion in
2. The embolic event was fatal in 32% of the cases and
led to persistent neurologic disabilities in 28% of the pa-
tients. Patients were receiving oral anticoagulation before
their embolic event in 36% of the cases, and 40% of the pa-
tients had evidence of atrial fibrillation or a history of recur-
rent AF before the embolic event. Finally, 19.6% of the
patients were receiving anticoagulants during follow-up
(mostly for atrial fibrillation treatment). Hemorrhages
occurred in 28 patients (linearized annual incidence,
0.9% per patient/year; actuarial freedom from hemorrhagic
event, 88%  3%, at 10 years), leading to death in 14.
Long-Term Outcome in Selected Subgroups
The Freestyle bioprosthesis showed excellent perfor-
mance and durability in the younger patients of the cohort
(age<65 years at implantation, n ¼ 45). The 10-year actu-
arial survivals from all-cause, cardiovascular, and valve-
related mortality were 69%  9%, 83%  7%, and
87%  6%, respectively (Figure 2, A). SVD was observed
in 4 patients and led to reintervention in all of them (actu-
arial freedom from SVD 89% 6% and actual cumulative
incidence of SVD 9% at 10 years) (Figure 2, B and C).
Moreover, we analyzed outcome in patients aged 80
years or more at implantation (n ¼ 120) and observed
that the 10-year actuarial survival from cardiovascular
and valve-related mortality were 41%  9% and
50%  10%, respectively.
We observed no difference in outcome in patients who
received a bioprosthesis with a diameter of 21 mm or less
(n ¼ 234) compared with the other patients (prosthesis
diameter>21 mm), as demonstrated by the 10-year actu-
arial survival freedom from cardiovascular death (66% 
6% vs 68%  4%, respectively, P ¼ .93), valve-related
mortality (66%  6% vs 72%  4%, respectively,
P ¼ .62), and SVD (95%  2% vs 94%  3%, respec-
tively, P ¼ .95). Finally, we did not observe any significant
impact of impaired LVEF on outcome. Although therewas a
trend toward a higher cardiovascular mortality (10-year
actuarial survival from cardiovascular death: 62%  7%
vs 71%  4%, respectively, P ¼ .13), the patients with a
baseline LVEF of 50% or less (n ¼ 111) showed compara-
ble 10-year survivals from valve-related mortality (68% 
8% vs 72% 4%, respectively, P¼ .52) and SVD (98%The Journal of Thoracic and Car2% vs 94%  2%, respectively, P ¼ .46) as the patients
with baseline LVEF greater than 50%.
Predictors of Long-Term Outcome After Freestyle
Implantation
Table 3 shows the predictors of cardiovascular death in
univariable and multivariable analyses. Cox regression
analysis revealed that age at implantation, presence of cor-
onary artery disease, and preoperative creatinine clearance
less than 60mL/min/m2 were independent predictors of car-
diovascular mortality after adjustment for confounding
factors.
Furthermore, we also analyzed predictors of valve-
related mortality in these patients (Table 4). We observed
that age at implantation and diabetes mellitus independently
predicted valve-related mortality. There was no significant
effect of other patients’ clinical characteristics, operative
technique, concomitant procedure, or device size on the
outcome in the whole cohort.
DISCUSSION
The expanding use of valvular bioprostheses among a
wide range of patients (including younger patients) high-
lights the need for durable, efficient, and safe devices.
The Freestyle bioprosthesis is a xenograft composed of a
thin synthetic sewing cuff attached to a preserved porcine
aortic root. The stent-free design allows an excellent con-
formability of the valve with the native aortic root, leading
to increased larger effective orifice area12 and less turbulent
flow13 compared with conventional stented bioprostheses
(CSBs). SLBs have a better hemodynamic profile and
demonstrate lower transvalvular gradient than CSBs.4,14
Moreover, the absence of struts could theoretically
impede the degeneration process affecting all
bioprostheses, because this phenomenon usually starts on
the attachment zones between the leaflets and the struts in
CSB, and thus leads to longer durability.15,16 Finally, the
anticalcification treatment of the bioprosthesis might
improve its potential longevity. Of note, recent results
showed a 97.9%  0.6% freedom of SVD at 10 years for
patients who received the Medtronic Mosaic bioprosthesis
(a third-generation alpha-amino oleic acid–treated porcine
valve mounted on a stent).17 Because the Mosaic and Free-
style bioprostheses differ only by the presence of the stent
and show comparable long-term durability, these data might
suggest that the demineralization process applied to these
devices could largely account for their excellent long-
term durability.
Despite these potential benefits, the use of SLB is
highly variable among institutions worldwide.18-20 These
paradoxical results might be explained by the concerns
raised regarding SLB real advantages over their
counterparts.1,21 Major criticisms relate to the increased
complexity and higher surgical risk for SLB implantation,diovascular Surgery c Volume 148, Number 5 1907
FIGURE 2. Kaplan–Meier actuarial survival curves for all-cause, cardiovascular, valve-related mortality (A), and SVD (B) in patients aged less than 65
years (n ¼ 45). Cumulative incidence of SVD (C). SVD, Structural valve deterioration.
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durability of these bioprostheses and long-term outcome.1,2
Different authors have reported encouraging long-term1908 The Journal of Thoracic and Cardiovascular Sur(>9 years) results with the use of the Freestyle bioprosthesis
for AVR, regardless of the implantation technique (subcoro-
nary or full aortic root replacement).19,22-24 In these differentgery c November 2014
TABLE 3. Predictors of long-term cardiovascular mortality
Univariable analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Age (per y) 1.06 (1.03-1.09) <.001 1.15 (1.08-1.23) <.001
Female gender 0.91 (0.64-1.30) .61
Body surface area (per unit) 0.35 (0.13-0.94) .04 — >.1
Preoperative TA mean gradient (per mm Hg) 0.99 (0.97-1.00) .06 — >.1
Coronary artery disease 1.57 (1.10-2.24) .014 1.72 (1.0-2.99) .05
Associated surgical procedure 1.13 (0.78-1.65) .52
Complete root replacement technique 0.94 (0.35-2.55) .9
Previous cardiac surgery 1.03 (0.26-4.2) .96
Prosthesis diameter 21 mm 0.98 (0.69-1.40) .92
Preoperative endocarditis 2.93 (0.72-11.9) .13
Baseline LVEF (per%) 0.99 (0.70-1.0) .11
Preoperative creatinine clearance<60 mL/min/m2 2.11 (1.41-3.15) <.001 2.0 (1.15-3.47) .01
Diabetes mellitus 1.83 (1.21-2.77) .004 >.1
Preoperative PH 1.46 (0.94-2.25) .09 >.1
Likelihood ratio test P<.001. CI, Confidence interval; HR, hazard ratio; LVEF, left ventricular ejection fraction; TA, transaortic; PH, pulmonary hypertension.
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and the freedom from SVD ranged from 91% to 97%. Our
present results are in line with these previous observations
and confirm the excellent durability of the Freestyle bio-
prosthesis in the long term, as highlighted by the limited inci-
dence of SVD. Although the overall survival in our cohort
was relatively low, this point might be explained by the
age of the patients at implantation (mean age, 74.5  9.6
years), because the mortality rate in this series was similar
to that observed in populations of similar age.19We observed
that the prominent deterioration mechanism for SVD
involved leaflet tear in the majority of cases and only limited
calcification. These data support the previous reports of the
‘‘wear and tear’’ phenomenon as the prominent mechanism
for SVD in the Freestyle bioprosthesis16 and the beneficial
role of the alpha-amino oleic acid valve pre-treatment to pre-
vent calcification in vivo.TABLE 4. Predictors of long-term valve-related mortality
Univa
HR (95% C
Age (per y) 1.07 (1.04-1.1
Female gender 1.09 (0.73-1.6
Body surface area (per unit) 0.40 (0.14-1.2
Preoperative transaortic mean gradient (per mm Hg) 0.99 (0.98-1.0
Coronary artery disease 1.43 (0.96-2.1
Associated surgical procedure 1.28 (0.85-1.9
Complete root replacement technique 1.15 (0.42-3.1
Prosthesis diameter 21 mm 1.10 (0.75-1.6
Previous cardiac surgery 1.90 (0.60-6.0
Preoperative endocarditis 1.61 (0.22-11
Baseline LVEF (per%) 0.99 (0.98-1.0
Preoperative creatinine clearance<60 mL/min/m2 1.32 (0.82-2.1
Diabetes mellitus 1.57 (0.98-2.5
Preoperative PH 1.35 (0.83-2.2
Likelihood ratio test, P<.001. CI, Confidence interval; HR, hazard ratio; LVEF, left vent
The Journal of Thoracic and CarThe comparison between SLB and CSB for survival
currently relies on conflicting data, and the putative advan-
tage of the SLB over stented ones remains debated. Howev-
er, when analyzing the literature, one should bear in mind
that these results are inhomogeneous, because they were ob-
tained from studies investigating several SLB types, each
with a specific design and specific anti-calcification treat-
ment. These features might account for the differences
observed in durability and structural deterioration.25 Thus,
the Toronto stentless porcine valve (St Jude Medical, Min-
neapolis, Minn) showed acceptable results on midterm clin-
ical outcome, but late accelerated structural failure after 8
years.3,26 We did not observe this phenomenon in the
present cohort, and the incidence of SVD and valve-
related mortality appeared to be stable in time when
compared with midterm results,5 supporting the previous
reports regarding the excellent durability of the Freestyleriable analysis Multivariable analysis
I) P value HR (95% CI) P value
1) <.001 1.08 (1.05-1.13) <.001
0) .71
0) .10 — >.1
1) .31
1) .08 — >.1
2) .24
5) .78
3) .63
) .27
.6) .64
1) .63
3) .26
1) .06 1.62 (1.01-2.59) .046
0) .23
ricle ejection fraction; PH, pulmonary hypertension.
diovascular Surgery c Volume 148, Number 5 1909
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available on biological prostheses durability have been
obtained in observational cohort studies. Thus, a direct
comparison between the Freestyle bioprosthesis and the
CSB is limited by the potential differences in baseline
population characteristics,22,25 yet these methodological
biases could be overcome by randomized clinical trials.
Unfortunately, such data are rare for the Freestyle valve.
However, El-Hamamsy and colleagues27 observed a better
durability and significantly less SVD of the Freestyle device
when compared with the homograft for aortic root replace-
ment.27 Furthermore, Lehman and colleagues3 observed
that survival might be improved by using the Freestyle bio-
prosthesis. Taken together, these different data strongly sug-
gest that the Freestyle bioprosthesis performs similar to
CSB and represents a valuable option for AVR in the gen-
eral population. However, SLBmight confer a disadvantage
in case of future transaortic valve implantation (TAVI).
Because ‘‘valve in valve’’ TAVI emerged as a therapeutic
option in elderly patients for redo procedures in degener-
ated bioprosthesis,28-30 concerns have been raised
regarding SLB, which may be more prone to coronary
coverage during TAVI for prosthetic failure because of to
their leaflet height and lack of sinuses or a stent.1 Dvir
and colleagues29 observed that valve-in-valve procedures
for SLB degeneration created a higher rate of coronary os-
tial obstruction than the stented valves.
The evolution of the younger (<65 years) and older
(>80 years) patients in this cohort also deserves special
consideration. The use of conventional biological prosthe-
ses is usually avoided in younger patients because of the
increased risk of device degradation leading to increased
rates of SVD1 (as high as 26%, 15 years after AVR31).
In the present study, we observed an 89% of freedom
from SVD at 10 years, confirming our previous midterm
analysis5 and other long-term outcome results.32 Thus,
the putative advantage of the Freestyle bioprosthesis
over CSB and in terms of durability for this special group
of patients seems justified. The Freestyle bioprosthesis
may represent an alternative to a homograft in young pa-
tients27 and could be considered when a bioprosthesis is
required because the risk for eventual reoperation is
known to be similar to that for primary isolated AVR.33
In this young (and often very active) population, a full
root replacement might be an attractive option when the
annulus size is less than 23 mm, to ensure optimal hemo-
dynamics in these physically demanding patients.34
Finally, we also observed acceptable long-term survival
in a large cohort of subjects aged more than 80 years (in
consideration of the life expectancy of these patients in
the general population). Although the implantation of
SLB remains highly debated in this subpopulation consid-
ering the higher technical complexity and longer cardio-
pulmonary bypass time, these results are encouraging1910 The Journal of Thoracic and Cardiovascular Surand in line with data previously reported by Ennker and
colleagues.35 Thus, the Freestyle bioprosthesis may be a
valuable option for AVR in octogenarians.5Study Limitations
The present study is an observational assessment of out-
comes. Patients were not randomly assigned to various ther-
apies, and comparison between inherently dissimilar groups
is problematic. Clinical follow-up was available through 12
years, but hemodynamic outcomes were not measured dur-
ing this period in all patients, which does not allow us to
draw any conclusion regarding this aspect, especially about
long-term evolution and left ventricular remodeling.CONCLUSIONS
The use of the Freestyle bioprosthesis for AVR resulted in
good long-term cardiovascular survival at any age in this
all-comers 500-patient cohort. These data suggest that this
bioprosthesis could be considered as a valuable option for
AVR, particularly for young patients aged more than 30
years who refuse the use of mechanical valves.
The authors thank Emmanuelle Pineau, MD, for data collection
and database management and Marie Cecile Perier, MSc, for addi-
tional statistics analysis.References
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